Cytokine expression and cancer detection

Medical Science Monitor

Volumn 15, Issue 3, 2009, Pages

  Yoo, So Young ^a,b   Lee, Sang Yup ^a   Yoo, Nae Choon ^c  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Cancer detection; Cytokine; Development of clinical test

Indexed keywords

ALPHA INTERFERON; ANGIOGENIN; BETA INTERFERON; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; PLATELET DERIVED GROWTH FACTOR; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANGIOGENESIS; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL GROWTH; DISEASE SEVERITY; DNA POLYMORPHISM; HUMAN; KIDNEY CARCINOMA; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR GROWTH; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

CYTOKINES; EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 65349100532     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Lucey DR, Clerici M, Shearrer GM: Type 1 and type 2 cytokine dysregu- lation in human infectious neoplastic and inflammatory diseases. Clin Microbiol Rev, 1996; 9: 532-552
2. Elsasser-Beile U, von Kleist S, Stahle W et al: Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma. Cancer, 1993; 71: 231-236
3. Kanazawa H: Role of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Med Sci Monit, 2007; 13(11): RA189-RA95
4. Lelbach A, Muzes G, Feher J: Current perspectives of catabolic mediators of cancer cachexia. Med Sci Monit, 2007; 13(9): RA168-RA73
5. Zumkeller W, Schofield PN: Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res, 1995; 15: 344-348
6. Rubin P, Johnston CJ, Williams JP et al: A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys, 1995; 33: 99-109
7. Lee TH: Cytokine networks in the pathogenesis of bronchial asthmia; Implications for therapy. J R Coll Physicians Lond, 1998; 32: 56-64
8. Luster MI, Germolec DR, Yoshida T et al: Endotoxin-induced cytokine gene expression and excretion in the liver. Hepatology, 1994; 19: 480-488
9. Bai L, Mao GP, Cao CP: Effects of inflammatory cytokines on the recurrence of liver cancer after an apparently curative operation. Journal of Digestive Disease, 2007; 8: 154-159 (Pubitemid 47161789)
10. Woodson K, Tangrea JA, Pollak M et al: Serum Insulin-like Growth Factor I: Tumor Marker or Etiologic Factor? A Prospective Study of Prostate Cancer among Finnish Men. Cancer Res, 2003; 63: 3991-3994
11. Srivani S, Pratibha K, Selvaluxmy G, Nagarajan B: Molecular logistics of cytokines in cervical cancer. Curr Sci, 2003; 84: 434-438
12. Lu H, Shu XO, Cui Y et al: Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res, 2000; 65: 5015-5019
13. Hefler LA, Grimm C, Ackermann S et al: An Interleukin-6 Gene Promoter Polymorphism Influences the Biological Phenotype of Ovarian Cancer. Cancer Res, 2003; 63: 3066-3068
14. Macarthur M, Hold GL, El-Omar EM: Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol, 2004; 286: G515-G520
15. Negus RPM, Balkwill FR: Cytokines in tumour growth, migration and metastasis. World J Urol, 1996; 14: 157-165 (Pubitemid 126775157)
16. Mantovani A: Tumor-associated macrophages in neoplastic progression: a paradigm for the in vitro function of chemokines. Lab Invest, 1994; 71: 5-16
17. Singer C, Rasmussen A, Smith HS et al: Malignant breast epithelium selects for Insulin-like Growth Factor II expression in breast stroma: evidence for paracrine function. Cancer Res, 1995; 55: 2448-2454
18. Naylor MS, Stamp GWH, Foulkes WD et al: Tumor necrosis factor and its receptors in human ovarian cancer: potential role in disease progression. J Clin Invest, 1997; 57: 141-146
19. Takahashi Y, Kitadai Y, Bucana CD et al: Expression of vascular endothelial growth factor and its receptor, KDR correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res, 1995; 55: 3964-3968
20. Braun B, Lange M, Oeckler R, Mueller MM: Expression of G-CSF and GM-CSF in Human Meningiomas Correlates with Increased Tumor Proliferation and Vascularization. J Neuro-Oncol, 2004; 68: 131-140
21. Sehgal PB, Tamm I: Interleukin-6 enhances motility of breast cancer cells. Cancer Invest, 1990; 8: 661-663
22. Lewis CE, Leek R, Harris A, McGee JO'D: Cytokine regulation of an- giogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol, 1995; 57: 747-751
23. Parhar RS, Shi Y, Zou M et al: Effects of cytokine-mediated modulation of nm23 expression on the invasion and metastatic behaviors of B16F10 melanoma cells. Int J Cancer, 1995; 60: 204-210
24. ten Kate M, Hofland LJ, van Koetsveld PM et al: Pro-Inflammatory Cytokines Affect Pancreatic Carcinoma Cell. Endothelial Cell Interactions. J Pancreas, 2006; 7: 454-464
25. Shi Q, Abbruzzese JL, Huang S et al: Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res, 1999; 5: 3711-3721
26. Thomas P, Hayashi H, Zimmer R, Forse RA: Regulation of cytokine production in carcinoembryonic antigen stimulated Kupffer cells by beta-2 adrenergic receptors: implications for hepatic metastasis. Cancer Lett, 2004; 209: 251-257
27. Luo J-L, Tan W, Ricono JM et al: Nuclear cytokine-activated IKKalpha ontrols prostate cancer metastasis by repressing Maspin. Nature, 2007; 446: 690-694
28. Koizumi K, Hojo S, Akashi T et al: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci, 2007; 98: 1652-1658
29. Krippl P, Langsenlehner U, Renner W et al: A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer, 2003; 106: 468-471
30. Lin CC, Wu HC, Tsai FJ et al: Vascular endothelial growth factor gene -460 C/T polymorphism is a biomarker for prostate cancer. Urology, 2003; 62: 374-377
31. Goswami S, Wang W, Wyckoff JB, Condeelis JS: Breast Cancer Cells Isolated by Chemotaxis from Primary Tumors Show Increased Survival and Resistance to Chemotherapy. Cancer Res, 2004; 64: 7664-7667
32. Dunlop RJ, Campbell CW: Cytokines and Advanced Cancer. J Pain Symptom Manage, 2000; 20: 214-232
33. Hirota S, Isozaki K, Moriyama Y et al: Gain of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998; 279: 577-580
34. Yoshimura A, Longmore G, Lodish HF: Point mutation in the exop- lamic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenecity. Nature, 1990; 348: 647-649
35. Lacronique V, Boureux A, Valle VD et al: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science, 1997; 278: 1309-1312
36. Meydan N, Grunberger T, Dadi H et al: Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature, 1996; 379: 645-648
37. Heinrich PC, Behrmann I, Haan S et al: Principles of interleukin (IL)-6- type cytokine signalling and its regulation. Biochem J, 2003; 374: 1-20
38. Yeh BK, Igarashi M, Eliseenkova AV et al: Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci USA, 2003; 100: 2266-2271
39. Jang JH: Identification and characterization of soluble isoform of fibroblast growth factor receptor 3 in human SaOS-2 osteosarcoma cells. Biochem Biophys Res Commun, 2002; 292: 378-382
40. Ezzat S, Zeng L, Lu S, Asa SL: A soluble domain netative blast growht factor receptor 4 isoform in human MCF-7 breast cancer cells. Biochem Biophy Res Commun, 2001; 287: 60-65
41. Vickers SM, Huang ZQ, MacMillan-Crow L et al: Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy. J Gastrointest Surg, 2002; 6: 546-553
42. Jang JH, Shin KH, Park JG: Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res, 2001; 61: 3541-3543
43. Kwabi-Addo B, Ropiquet F, Firi D, Ittmann M: Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate, 2001; 46: 163-172
44. Abbass SA, Asa SL, Ezzat S: Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab, 2001; 82: 1160-1166
45. Korpelainen EI, Alitalo K: Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol, 1998; 10: 159-164
46. Karkkainen MJ, Ferrell RE, Lawrence EC et al: Missense mutations interfere with VEGFR-3 signaling in primary lymphoedema. Nature Genet, 2000; 25: 153-159
47. Borg JP, deLapeyriere O, Noguchi T et al: Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase. Oncogene, 1995; 10: 973-984
48. Karamysheva AF, Shushanov SS, Adelaide J et al: Expression of the FLT4/VEGFR3 receptor tyrosine kinase encoding gene in hepatic tumors. Int J Oncol, 1996; 8: 921-924
49. Skobe M, Brown LF, Tognazzi K et al: Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS- associated Kaposi's sarcoma. J Invest Dermatol, 1999; 113: 1047-1053
50. Shushanov S, Bronstein M, Adelaide J et al: VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer, 2000; 86: 47-52
51. Strassmann G, Masui Y, Chizzonite R, Fong M: Mechanisms of experimental cancer cachexia: Local involvement of IL-1 in colon-26 tumor. J Immunol, 1993; 150: 2341-2345
52. Lieksche GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med, 1992; 327: 28-34
53. O'Reilly MS, Holmgren L, Shin Y et al: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung catcinoma. Cell, 1994; 79: 315-328
54. Senger DR, Van De Water L, Braun LF, Nasy JA: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Mtg Rev, 1993; 12: 303-324
55. Rak J, Mitwuhashi Y, Bayko L, Filmus J: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res, 1995; 55: 4575-4580
56. Strieter RM, Polverini PJ, Arenberg DA, Kkunkel SL: The role of CXC chemokines as regulators of angiogenesis. Shock, 1995; 4: 155-160
57. Angiolillo AL, Sgadari C, Taub DD, Liao F: Human interferon-inducible protein 10 is potent inhibitor of angiogenesis in vivo. J Exp Med, 1995; 182: 155-162
58. Taga K, Yamauchi A, Kabashima K et al: Target-induced death by apoptosis in human lymphokine-activated natural killer cells. Blood, 1996; 87: 2411-2418
59. Ito R, Kitadai Y, Kyo E et al: Interleukin 1a acts as an autocrine growth simulator for human gastric carcinoma cells. Cancer Res, 1993; 55: 4102-4106
60. Voorzanger N, Touitou R, Garcia E et al: Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkins Lymphoma Cells and act as cooperative growth factors. Cancer Res, 1996; 56: 5499-5505
61. Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and auto- crine growth factor in human prostatic carcinoma cells in vitro. Cancer Res, 1997; 57: 141-146 (Pubitemid 27020343)
62. Hamada J, Cavanaugh P, Miki K, Nicolson G: A paracrine migration- stimulating factor for metastatic tumor cells secreted by mouse hepatic sinusoidal endothelial cells: identification as complement component 3b. Cancer Res, 1993; 53: 4418-4423
63. Wakabayashi H, Cavanaugh P, Nicolson G: Purification and identification of mouse lung microvessel endothelial cell-derived chemoattractant for lung-metastasizing murine large-cell lymphoma cells: identification as mouse monocyte chemotactic protein-1. Cancer Res, 1995; 55: 4458-4464
64. Inoue T, Cavanaugh P, Nicolson G: Differences in transferrin response and numbers of transferrin receptos in rat and human mammary carcinoma lines of different metastativ potentials. J Cell Physiol, 1993; 156: 212-217
65. Rivas J, Ullrich S: The role of IL-4, IL-10, and TNF-a in the immune suppression induced by ultraviolet radiation. J Leukoc Biol, 1994; 56: 769-775
66. Markowitz S, Wang J, Myeroff L et al: Inactivation of the type II TGF- receptor in colon cancer cells with microsatellite instability. Science, 1995; 268: 1336-1338
67. Myeroff LL, Parsons R, Kim SJ et al: A TGF-p receptor type II gene mutation common in colon anc gastric but rare in endometrial cancers with microsatellite instability. Cancer Res, 1995; 55: 5545-5547